We are reducing risk by broadening and balancing our portfolio, diversifying into new product areas that show potential, while also fully capturing opportunities for our products across all geographic boundaries.
Specifically, we expect to generate future sales growth by strengthening our core pharmaceuticals business and supplementing it with increased investment in growth areas such as vaccines, biopharmaceuticals and consumer healthcare.
We are also seeking to unlock the geographic potential of our businesses, particularly in emerging markets and Japan.
We have made good progress on this priority during 2008, and we believe there remain many opportunities for GSK to diversify further.

“It's important that we generate more growth with less risk.”
